NCT02402699View on ClinicalTrials.gov

Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan

CompletedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

March 23, 2017

Study Completion Date

March 23, 2017

Conditions
Advanced MelanomaHepatitis BHepatitis C
Trial Locations (1)

Unknown

Local Institution, Taipei

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY